What is Bidil?
Isosorbide dinitrate/hydralazine is a fixed dose combination drug treatment specifically indicated for African Americans with congestive heart failure. It is a combination of hydralazine (an antihypertensive) and isosorbide dinitrate (a vasodilator). It is the first race-based prescription drug in the United States.
The combination preparation is marketed in the United States under the trade name BiDil by Arbor Pharmaceuticals, Inc. which purchased the rights to market the drug in December 2011 from NitroMed.